Judge Denies Novo Nordisk Injunction Bid Against Lilly's Weight-Loss Drug Ads
LLY sits 58% above its 52-week low of $809.63.
Summary
A federal judge in New Jersey denied Novo Nordisk's request to block Eli Lilly's Zepbound and Mounjaro advertising, ruling Novo failed to show the ads caused irreparable harm. Judge Zahid Quraishi found Lilly's ads had at most negligible market impact from April to July, with Novo's prescriptions holding steady, and said money damages could cover any nontrivial harm. The ruling keeps Lilly's comparative ad campaign running in a market where Novo reported about $32 billion in combined obesity and Ozempic sales for 2025. Novo says the decision did not resolve whether the ads are false or misleading and the case continues, so this removes an immediate commercial threat to Lilly rather than ending the dispute.
At the time of this announcement, LLY was trading at $1,282.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2T. The 52-week trading range was $809.63 to $1,321.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.